Overexpression screens identify conserved dosage chromosome instability genes in yeast and human cancer

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 36, 2016, Pages 9967-9976

  Duffy, Supipi ^a   Fam, Hok Khim ^b,c   Wang, Yi Kan ^d   Styles, Erin B ^e   Kim, Jung Hyun ^f   Ang, J Sidney ^a   Singh, Tejomayee ^a   Larionov, Vladimir ^f   Shah, Sohra P ^d   Andrews, Brenda ^e   Boerkoel, Cornelius F ^b,c   Hieter, Philip ^a,c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d BRITISH COLUMBIA CANCER AGENCY   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Dosage chromosome instability; Overexpression; Rhabdomyosarcoma; Synthetic dosage lethality|tdp1

Indexed keywords

PHOSPHODIESTERASE; RNA POLYMERASE II; TAF12 PROTEIN; TDP1 PROTEIN; TRICHOSTATIN A; UNCLASSIFIED DRUG; VALPROIC ACID; HDAC2 PROTEIN, HUMAN; HISTONE DEACETYLASE; HISTONE DEACETYLASE 2; HYDROXAMIC ACID; RPD3 PROTEIN, S CEREVISIAE; SACCHAROMYCES CEREVISIAE PROTEIN; SMALL INTERFERING RNA; TAF12 PROTEIN, HUMAN; TATA BINDING PROTEIN ASSOCIATED FACTOR; TDP1 PROTEIN, S CEREVISIAE;

BUDDING YEAST; CHROMOSOMAL INSTABILITY; CONFERENCE PAPER; GENE AMPLIFICATION; GENE DELETION; GENE DOSAGE; GENE OVEREXPRESSION; GENETIC SCREENING; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; NONHUMAN; PRIORITY JOURNAL; RHABDOMYOSARCOMA; RHABDOMYOSARCOMA CELL LINE; TUMOR GENE; ANTAGONISTS AND INHIBITORS; GENE EXPRESSION REGULATION; GENETICS; MUTATION; PATHOLOGY; SACCHAROMYCES CEREVISIAE; TUMOR CELL LINE;

CELL LINE, TUMOR; CHROMOSOMAL INSTABILITY; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE 2; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; MUTATION; PHOSPHORIC DIESTER HYDROLASES; RHABDOMYOSARCOMA; RNA, SMALL INTERFERING; SACCHAROMYCES CEREVISIAE; SACCHAROMYCES CEREVISIAE PROTEINS; TATA-BINDING PROTEIN ASSOCIATED FACTORS; VALPROIC ACID;

EID: 84986250525     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1611839113     Document Type: Article

References (114)

1. Bayani J, et al. (2007) Genomic mechanisms and measurement of structural and numerical instability in cancer cells. Semin Cancer Biol 17(1):5-18.
2. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: The next generation. Cell 144(5):646-674.
3. Lengauer C, Kinzler KW, Vogelstein B (1997) Genetic instability in colorectal cancers. Nature 386(6625):623-627.
4. Stratton MR, Campbell PJ, Futreal PA (2009) The cancer genome. Nature 458(7239):719-724.
5. Dewhurst SM, et al. (2014) Tolerance of whole-genome doubling propagates chromosomal instability and accelerates cancer genome evolution. Cancer Discov 4(2):175-185.
6. Fisher R, Pusztai L, Swanton C (2013) Cancer heterogeneity: Implications for targeted therapeutics. Br J Cancer 108(3):479-485.
7. Horswell S, Matthews N, Swanton C (2013) Cancer heterogeneity and "the struggle for existence": Diagnostic and analytical challenges. Cancer Lett 340(2):220-226.
8. McBride M, Rida PCG, Aneja R (2015) Turning the headlights on novel cancer biomarkers: Inspection of mechanics underlying intratumor heterogeneity. Mol Aspects Med 45:3-13.
9. Stirling PC, et al. (2012) Mutability and mutational spectrum of chromosome transmission fidelity genes. Chromosoma 121(3):263-275.
10. Stirling PC, et al. (2011) The complete spectrum of yeast chromosome instability genes identifies candidate CIN cancer genes and functional roles for ASTRA complex components. PLoS Genet 7(4):e1002057.
11. Yuen KWY, et al. (2007) Systematic genome instability screens in yeast and their potential relevance to cancer. Proc Natl Acad Sci USA 104(10):3925-3930.
12. Ouspenski II, Elledge SJ, Brinkley BR (1999) New yeast genes important for chromosome integrity and segregation identified by dosage effects on genome stability. Nucleic Acids Res 27(15):3001-3008.
13. Zhu J, et al. (2015) Single-cell based quantitative assay of chromosome transmission fidelity. G3 (Bethesda) 5(6):1043-1056.
14. Beroukhim R, et al. (2010) The landscape of somatic copy-number alteration across human cancers. Nature 463(7283):899-905.
15. Sanchez-Garcia F, et al. (2014) Integration of genomic data enables selective discovery of breast cancer drivers. Cell 159(6):1461-1475.
16. Vogelstein B, et al. (2013) Cancer genome landscapes. Science 339(6127):1546-1558.
17. Zack TI, et al. (2013) Pan-cancer patterns of somatic copy number alteration. Nat Genet 45(10):1134-1140.
18. Fece de la Cruz F, Gapp BV, Nijman SMB (2015) Synthetic lethal vulnerabilities of cancer. Annu Rev Pharmacol Toxicol 55(1):513-531.
19. Janssen A, van der Burg M, Szuhai K, Kops GJPL, Medema RH (2011) Chromosome segregation errors as a cause of DNA damage and structural chromosome aberrations. Science 333(6051):1895-1898.
20. Manchado E, Malumbres M (2011) Targeting aneuploidy for cancer therapy. Cell 144(4):465-466.
21. McLornan DP, List A, Mufti GJ (2014) Applying synthetic lethality for the selective targeting of cancer. N Engl J Med 371(18):1725-1735.
22. van Pel DM, et al. (2013) An evolutionarily conserved synthetic lethal interaction network identifies FEN1 as a broad-spectrum target for anticancer therapeutic development. PLoS Genet 9(1):e1003254.
23. Tang Y-C, Williams BR, Siegel JJ, Amon A (2011) Identification of aneuploidy-selective antiproliferation compounds. Cell 144(4):499-512.
24. Bryant HE, et al. (2005) Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434(7035):913-917.
25. Farmer H, et al. (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434(7035):917-921.
26. Bian Y, et al. (2014) Synthetic genetic array screen identifies PP2A as a therapeutic target in Mad2-overexpressing tumors. Proc Natl Acad Sci USA 111(4):1628-1633.
27. Megchelenbrink W, Katzir R, Lu X, Ruppin E, Notebaart RA (2015) Synthetic dosage lethality in the human metabolic network is highly predictive of tumor growth and cancer patient survival. Proc Natl Acad Sci USA 112(39):12217-12222.
28. Kroll ES, Hyland KM, Hieter P, Li JJ (1996) Establishing genetic interactions by a synthetic dosage lethality phenotype. Genetics 143(1):95-102.
29. Measday V, et al. (2005) Systematic yeast synthetic lethal and synthetic dosage lethal screens identify genes required for chromosome segregation. Proc Natl Acad Sci USA 102(39):13956-13961.
30. Measday V, Hieter P (2002) Synthetic dosage lethality. Methods Enzymol 350:316-326.
31. Davoli T, et al. (2013) Cumulative haploinsufficiency and triplosensitivity drive aneuploidy patterns and shape the cancer genome. Cell 155(4):948-962.
32. Yang SW, et al. (1996) A eukaryotic enzyme that can disjoin dead-end covalent complexes between DNA and type I topoisomerases. Proc Natl Acad Sci USA 93(21): 11534-11539.
33. El-Khamisy SF, et al. (2005) Defective DNA single-strand break repair in spinocerebellar ataxia with axonal neuropathy-1. Nature 434(7029):108-113.
34. Interthal H, et al. (2005) SCAN1 mutant Tdp1 accumulates the enzyme-DNA intermediate and causes camptothecin hypersensitivity. EMBO J 24(12):2224-2233.
35. Pommier Y (2004) Camptothecins and topoisomerase I: A foot in the door. Targeting the genome beyond topoisomerase I with camptothecins and novel anticancer drugs: Importance of DNA replication, repair and cell cycle checkpoints. Curr Med Chem Anticancer Agents 4(5):429-434.
36. Pouliot JJ, Yao KC, Robertson CA, Nash HA (1999) Yeast gene for a Tyr-DNA phosphodiesterase that repairs topoisomerase I complexes. Science 286(5439):552-555.
37. Douglas AC, et al. (2012) Functional analysis with a barcoder yeast gene overexpression system. G3 (Bethesda) 2(10):1279-1289.
38. Spencer F, Gerring SL, Connelly C, Hieter P (1990) Mitotic chromosome transmission fidelity mutants in Saccharomyces cerevisiae. Genetics 124(2):237-249.
39. Strathern J, Hicks J, Herskowitz I (1981) Control of cell type in yeast by the mating type locus. The alpha 1-alpha 2 hypothesis. J Mol Biol 147(3):357-372.
40. Mishra PK, et al. (2011) Misregulation of Scm3p/HJURP causes chromosome instability in Saccharomyces cerevisiae and human cells. PLoS Genet 7(9):e1002303.
41. Sarafan-Vasseur N, et al. (2002) Overexpression of B-type cyclins alters chromosomal segregation. Oncogene 21(13):2051-2057.
42. Mani R, St Onge RP, Hartman JL, 4th, Giaever G, Roth FP (2008) Defining genetic interaction. Proc Natl Acad Sci USA 105(9):3461-3466.
43. Costanzo M, Baryshnikova A, Myers CL, Andrews B, Boone C (2011) Charting the genetic interaction map of a cell. Curr Opin Biotechnol 22(1):66-74.
44. Jackson SP, Bartek J (2009) The DNA-damage response in human biology and disease. Nature 461(7267):1071-1078.
45. Alvaro D, Lisby M, Rothstein R (2007) Genome-wide analysis of Rad52 foci reveals diverse mechanisms impacting recombination. PLoS Genet 3(12):e228.
46. Stirling PC, et al. (2012) R-loop-mediated genome instability in mRNA cleavage and polyadenylation mutants. Genes Dev 26(2):163-175.
47. Tong AH, et al. (2001) Systematic genetic analysis with ordered arrays of yeast deletion mutants. Science 294(5550):2364-2368.
48. Barber TD, et al. (2008) Chromatid cohesion defects may underlie chromosome instability in human colorectal cancers. Proc Natl Acad Sci USA 105(9):3443-3448.
49. Balakrishnan R, et al. (2012) YeastMine-An integrated data warehouse for Saccharomyces cerevisiae data as a multipurpose tool-kit. Database (Oxford) 2012(0):bar062.
50. O'Brien KP, Remm M, Sonnhammer ELL (2005) Inparanoid: A comprehensive database of eukaryotic orthologs. Nucleic Acids Res 33(Database issue):D476-D480.
51. Casimiro MC, et al. (2012) ChIP sequencing of cyclin D1 reveals a transcriptional role in chromosomal instability in mice. J Clin Invest 122(3):833-843.
52. Spruck CH, Won KA, Reed SI (1999) Deregulated cyclin E induces chromosome instability. Nature 401(6750):297-300.
53. Lee H-S, et al. (2013) A new assay for measuring chromosome instability (CIN) and identification of drugs that elevate CIN in cancer cells. BMC Cancer 13(1):252.
54. Yang X, et al. (2011) A public genome-scale lentiviral expression library of human ORFs. Nat Methods 8(8):659-661.
55. Tong Y, et al. (2015) Cross-species genomics identifies TAF12, NFYC, and RAD54L as choroid plexus carcinoma oncogenes. Cancer Cell 27(5):712-727.
56. Fam HK, et al. (2013) TDP1 and PARP1 deficiency are cytotoxic to rhabdomyosarcoma cells. Mol Cancer Res 11(10):1179-1192.
57. Yu J, Shannon WD, Watson MA, McLeod HL (2005) Gene expression profiling of the irinotecan pathway in colorectal cancer. Clin Cancer Res 11(5):2053-2062.
58. Liu C, et al. (2007) Increased expression and activity of repair genes TDP1 and XPF in non-small cell lung cancer. Lung Cancer 55(3):303-311.
59. Dagher R, Helman L (1999) Rhabdomyosarcoma: An overview. Oncologist 4(1):34-44.
60. Liu C, Pouliot JJ, Nash HA (2002) Repair of topoisomerase I covalent complexes in the absence of the tyrosyl-DNA phosphodiesterase Tdp1. Proc Natl Acad Sci USA 99(23):14970-14975.
61. Liu C, Pouliot JJ, Nash HA (2004) The role of TDP1 from budding yeast in the repair of DNA damage. DNA Repair (Amst) 3(6):593-601.
62. Pouliot JJ, Robertson CA, Nash HA (2001) Pathways for repair of topoisomerase I covalent complexes in Saccharomyces cerevisiae. Genes Cells 6(8):677-687.
63. Vance JR, Wilson TE (2002) Yeast Tdp1 and Rad1-Rad10 function as redundant pathways for repairing Top1 replicative damage. Proc Natl Acad Sci USA 99(21):13669-13674.
64. Kapitzky L, et al. (2010) Cross-species chemogenomic profiling reveals evolutionarily conserved drug mode of action. Mol Syst Biol 6:451.
65. He X, et al. (2007) Mutation of a conserved active site residue converts tyrosyl-DNA phosphodiesterase I into a DNA topoisomerase I-dependent poison. J Mol Biol 372(4):1070-1081.
66. Interthal H, Pouliot JJ, Champoux JJ (2001) The tyrosyl-DNA phosphodiesterase Tdp1 is a member of the phospholipase D superfamily. Proc Natl Acad Sci USA 98(21): 12009-12014.
67. Takashima H, et al. (2002) Mutation of TDP1, encoding a topoisomerase I-dependent DNA damage repair enzyme, in spinocerebellar ataxia with axonal neuropathy. Nat Genet 32(2):267-272.
68. Gajewski S, et al. (2012) Analysis of the active-site mechanism of tyrosyl-DNA phosphodiesterase I: A member of the phospholipase D superfamily. J Mol Biol 415(4):741-758.
69. Robinson MD, Grigull J, Mohammad N, Hughes TR (2002) FunSpec: A web-based cluster interpreter for yeast. BMC Bioinformatics 3:35.
70. Kurdistani SK, Grunstein M (2003) Histone acetylation and deacetylation in yeast. Nat Rev Mol Cell Biol 4(4):276-284.
71. Shahbazian MD, Grunstein M (2007) Functions of site-specific histone acetylation and deacetylation. Annu Rev Biochem 76(1):75-100.
72. West AC, Johnstone RW (2014) New and emerging HDAC inhibitors for cancer treatment. J Clin Invest 124(1):30-39.
73. Reynolds MF, Sisk EC, Rasgon NL (2007) Valproate and neuroendocrine changes in relation to women treated for epilepsy and bipolar disorder: A review. Curr Med Chem 14(26):2799-2812.
74. Shi P, et al. (2014) Valproic acid sensitizes pancreatic cancer cells to natural killer cellmediated lysis by upregulating MICA and MICB via the PI3K/Akt signaling pathway. BMC Cancer 14(1):370.
75. Yang FQ, et al. (2014) VPA inhibits renal cancer cell migration by targeting HDAC2 and down-regulating HIF-1α. Mol Biol Rep 41(3):1511-1518.
76. Vigushin DM, et al. (2001) Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin Cancer Res 7(4):971-976.
77. Chang J, et al. (2012) Differential response of cancer cells to HDAC inhibitors trichostatin A and depsipeptide. Br J Cancer 106(1):116-125.
78. Moreira JMA, Scheipers P, Sørensen P (2003) The histone deacetylase inhibitor Trichostatin A modulates CD4+ T cell responses. BMC Cancer 3(1):30.
79. McManus KJ, Barrett IJ, Nouhi Y, Hieter P (2009) Specific synthetic lethal killing of RAD54B-deficient human colorectal cancer cells by FEN1 silencing. Proc Natl Acad Sci USA 106(9):3276-3281.
80. Shaukat Z, et al. (2015) Chromosomal instability causes sensitivity to metabolic stress. Oncogene 34(31):4044-4055.
81. Ho CH, et al. (2009) A molecular barcoded yeast ORF library enables mode-of-action analysis of bioactive compounds. Nat Biotechnol 27(4):369-377.
82. Sopko R, et al. (2006) Mapping pathways and phenotypes by systematic gene overexpression. Mol Cell 21(3):319-330.
83. Veitia RA (2005) Gene dosage balance: Deletions, duplications and dominance. Trends Genet 21(1):33-35.
84. Flemming D, et al. (2009) Two structurally distinct domains of the nucleoporin Nup170 cooperate to tether a subset of nucleoporins to nuclear pores. JCellBiol185(3):387-395.
85. Caldon CE, et al. (2013) Cyclin E2 induces genomic instability by mechanisms distinct from cyclin E1. Cell Cycle 12(4):606-617.
86. Santarius T, Shipley J, Brewer D, Stratton MR, Cooper CS (2010) A census of amplified and overexpressed human cancer genes. Nat Rev Cancer 10(1):59-64.
87. Mengus G, et al. (1995) Cloning and characterization of hTAFII18, hTAFII20 and hTAFII28: Three subunits of the human transcription factor TFIID. EMBO J 14(7):1520-1531.
88. Giam M, Rancati G (2015) Aneuploidy and chromosomal instability in cancer: A jackpot to chaos. Cell Div 10(1):3, 10.1186/s13008-015-0009-7.
89. Dean RA, et al. (2014) Identification of a putative Tdp1 inhibitor (CD00509) by in vitro and cell-based assays. J Biomol Screen 19(10):1372-1382.
90. Goldstein M, Meller I, Issakov J, Orr-Urtreger A (2006) Novel genes implicated in embryonal, alveolar, and pleomorphic rhabdomyosarcoma: A cytogenetic and molecular analysis of primary tumors. Neoplasia 8(5):332-343.
91. Bakhoum SF, Compton DA (2012) Chromosomal instability and cancer: A complex relationship with therapeutic potential. J Clin Invest 122(4):1138-1143.
92. Yuen KWY (2010) Chromosome instability (CIN), aneuploidy and cancer. Encyclopedia of Life Sciences (John Wiley & Sons, Ltd, Chichester, UK). Available at: onlinelibrary.wiley. com/resolve/doi?DOI=10.1002/9780470015902.a0022413. Accessed February 4, 2016.
93. Helleday T, Petermann E, Lundin C, Hodgson B, Sharma RA (2008) DNA repair pathways as targets for cancer therapy. Nat Rev Cancer 8(3):193-204.
94. Hosoi H (2015) Current status of treatments for children with rhabdomyosarcoma in the United States and Japan. Pediatr Int 58(2):81-87.
95. Mascarenhas L, et al. (2010) Randomized phase II window trial of two schedules of irinotecan with vincristine in patients with first relapse or progression of rhabdomyosarcoma: A report from the Children's Oncology Group. J Clin Oncol 28(30):4658-4663.
96. Pappo AS, et al.; Children's Oncology Group (2007) Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: The Children's OncologyGroup.JClinOncol25(4):362-369.
97. D'Arpa P, Beardmore C, Liu LF (1990) Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons. Cancer Res 50(21):6919-6924.
98. Huang SN, Pommier Y, Marchand C (2011) Tyrosyl-DNA Phosphodiesterase 1 (Tdp1) inhibitors. Expert Opin Ther Pat 21(9):1285-1292.
99. Marchand C, et al. (2014) Biochemical assays for the discovery of TDP1 inhibitors. Mol Cancer Ther 13(8):2116-2126.
100. Kaluarachchi Duffy S, et al. (2012) Exploring the yeast acetylome using functional genomics. Cell 149(4):936-948.
101. Sharifpoor S, et al. (2012) Functional wiring of the yeast kinome revealed by global analysis of genetic network motifs. Genome Res 22(4):791-801.
102. Reid RJD, et al. (2011) Selective ploidy ablation, a high-throughput plasmid transfer protocol, identifies new genes affecting topoisomerase I-induced DNA damage. Genome Res 21(3):477-486.
103. Hart T, et al. (2015) High-resolution CRISPR screens reveal fitness genes and genotype-specific cancer liabilities. Cell 163(6):1515-1526.
104. Boehm JS, Golub TR (2015) An ecosystem of cancer cell line factories to support a cancer dependency map. Nat Rev Genet 16(7):373-374.
105. Hamza A, et al. (2015) Complementation of yeast genes with human genes as an experimental platform for functional testing of human genetic variants. Genetics 201(3):1263-1274.
106. McLellan JL, et al. (2012) Synthetic lethality of cohesins with PARPs and replication fork mediators. PLoS Genet 8(3):e1002574.
107. Hu Y, et al. (2007) Approaching a complete repository of sequence-verified proteinencoding clones for Saccharomyces cerevisiae. Genome Res 17(4):536-543.
108. Carpenter AE, et al. (2006) CellProfiler: Image analysis software for identifying and quantifying cell phenotypes. Genome Biol 7(10):R100.
109. Lévesque N, Leung GP, Fok AK, Schmidt TI, Kobor MS (2010) Loss of H3 K79 trimethylation leads to suppression of Rtt107-dependent DNA damage sensitivity through the translesion synthesis pathway. J Biol Chem 285(45):35113-35122.
110. Chong YT, et al. (2015) Yeast proteome dynamics from single cell imaging and automated analysis. Cell 161(6):1413-1424.
111. Hall BM, Ma C-X, Liang P, Singh KK (2009) Fluctuation analysis CalculatOR: A web tool for the determination of mutation rate using Luria-Delbruck fluctuation analysis. Bioinformatics 25(12):1564-1565.
112. Deng M (2015) FirebrowseR: An "API" client for broads "firehose" pipeline. R package version 0.2.21. Available at firebrowse.org.
113. Cerami E, et al. (2012) The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov 2(5):401-404.
114. Gao J, et al. (2013) Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6(269):pl1.